Find and Pitch Jounalists, Get Your Story Covered

Tags: Multiple Myeloma Cancer Treatment Regimen Comparisons Pharmacist

	Profile	Recent Articles on Subject
1	1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	NICE nod for Darzalex with lenalidomide and dexamethasone - over 1 year ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis - 23 days ago Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma - 4 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 12 months ago Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - about 1 year ago
3	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma - about 1 month ago Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation - about 1 month ago Mezigdomide Combinations Show Promise in Multiple Myeloma - about 1 month ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 7 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Why Some Myeloma Patients Refuse Stem Cell Transplant - about 1 year ago
4	Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA Healthcareoncologypharmacyeducation	Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies - about 1 month ago Final Thoughts - 2 months ago Personalizing Treatments and Patient Education - 3 months ago Real-World Considerations for New Therapies - 4 months ago
5	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - about 2 months ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - about 2 months ago
6	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - about 2 months ago Arcellx to present positive data on multiple myeloma treatments - 3 months ago Scotland first in UK to approve new myeloma treatment - 5 months ago
7	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study - about 2 months ago Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma - 3 months ago Relapsed/Refractory Multiple Myeloma Treatment Advances With Three BiTE Therapy Options - 10 months ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - about 1 year ago
8	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - 3 months ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA Approves Earlier Use of CAR-T Products for Myeloma - 10 months ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - about 1 year ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 10 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago

Journalists covering myeloma